🔎 Trials Near Me

Utama › Kanser Ovari › Texas › San Antonio

Kajian klinikal Kanser Ovari di San Antonio, TX

31 kajian untuk Kanser Ovari sedang mencari peserta di lokasi dalam dan sekitar San Antonio (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Mengambil pesertaFasa 1/2
  • Research Site, San Antonio
Umur 18 hingga 130 · Semua jantina · Dikemas kini 5 Okt 2026 · NCT05417594

A Study of PHST001 in Advanced Solid Tumors

Mengambil pesertaFasa 1
  • START Center for Cancer Research - San Antonio, San Antonio
  • University of Texas (UT) Health, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT06840886

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Mengambil pesertaFasa 1
  • South Texas Accelerated Research Therapeutics (START), San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06465069

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Mengambil pesertaFasa 1/2
  • New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
Umur 12 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04585750

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

Mengambil pesertaFasa 1
  • NEXT Oncology - San Antonio /ID# 278606, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07278336

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

Mengambil pesertaFasa 1
  • NEXT Oncology - PARENT, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT07360314

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Mengambil pesertaFasa 2
  • Texas Oncology - San Antonio Medical Center - Research Drive /ID# 277735, San Antonio
Umur 18 ke atas · Wanita · Dikemas kini 22 Sep 2026 · NCT07059845

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Mengambil pesertaFasa 1/2
  • NEXT Oncology San Antonio, San Antonio
  • START Texas, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06128551

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Mengambil pesertaFasa 1/2
  • START Center for Cancer Research, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07109726

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Mengambil pesertaFasa 2
  • Texas Oncology-San Antonio Medical Center Pharmacy, San Antonio
Umur 18 hingga 99 · Wanita · Dikemas kini 15 Sep 2026 · NCT07023627

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Mengambil pesertaKajian pemerhatian
  • The University of Texas Health Science Center at San Antonio, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT05059444

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Mengambil pesertaFasa 1
  • START - San Antonio, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT06293898

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Mengambil pesertaFasa 3
  • University Of Texas Health Science Center -San Antonio ( Site 0095), San Antonio
  • Texas Oncology - San Antonio ( Site 8005), San Antonio
Umur 18 ke atas · Wanita · Dikemas kini 3 Sep 2026 · NCT06824467

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Mengambil pesertaFasa 1
  • START San Antonio, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Ogo 2026 · NCT06582017

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Mengambil pesertaFasa 1
  • UT Health San Antonio - MD Anderson Cancer Center, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Ogo 2026 · NCT06774963

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Mengambil pesertaFasa 1
  • Normunity Investigational Site, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Ogo 2026 · NCT07182149

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Mengambil pesertaFasa 1/2
  • START San Antonio, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Ogo 2026 · NCT05985655

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

Mengambil pesertaFasa 1/2
  • Clinical Trial Site, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT07749586

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Mengambil pesertaFasa 1
  • START - San Antonio, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT07444814

IDOV-Immune for Advanced Solid Tumors

Mengambil pesertaFasa 1
  • South Texas Accelerated Research Therapeutics, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT06910657

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Mengambil pesertaFasa 1/2
  • Texas Oncology - San Antonio, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Jul 2026 · NCT04657068

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Mengambil pesertaFasa 1
  • NEXT San Antonio, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Jul 2026 · NCT07524322

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Mengambil pesertaFasa 1/2
  • START San Antonio, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jul 2026 · NCT05768139

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Mengambil pesertaFasa 1/2
  • START, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Jun 2026 · NCT06993844

Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women

Mengambil pesertaSukarelawan sihat dialu-alukan
  • UT Health Science Center San Antonio, San Antonio
Umur 50 hingga 74 · Wanita · Dikemas kini 6 Mei 2026 · NCT00539162

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Mengambil pesertaFasa 1
  • NEXT Oncology San Antonio, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Apr 2026 · NCT07424547

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Mengambil pesertaFasa 1
  • START San Antonio, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Jan 2026 · NCT06234423

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Mengambil pesertaFasa 1
  • Dren Investigational Site, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jan 2026 · NCT06999187

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Mengambil pesertaFasa 1
  • Exelixis Clinical Site #3, San Antonio
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Sep 2025 · NCT05932862

Kajian Kanser Ovari di bandar lain

Kajian lain di San Antonio

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.